ZAS3 is a large zinc finger transcription repressor that binds the κB-motif via two signature domains of ZASN and ZASC. A loss-of-function study showed that lack of ZAS3 protein induced accelerated cell proliferation and tumorigenesis. Conversely, gain-of-function studies showed that ZAS3 repressed NFκB-activated transcription by competing with NFκB for the κB-motif. Based on these observations, we hypothesize that ZAS3 promotes apoptosis by interrupting anti-apoptotic activity of NFκB. Here, we present evidence that upon TNFα stimulation, ZAS3 inhibits NFκB-mediated cell survival and promotes caspase-mediated apoptosis. The inhibitory effect of ZAS3 on NFκB activity is mediated by neither direct association with NFκB nor disrupting nuclear localization of NFκB. Instead, ZAS3 repressed the expression of two key anti-apoptotic genes of NFκB, TRAF1 and TRAF2, thereby sensitizing cells to TNFα-induced cell death. Taken together, our data suggest that ZAS3 is a tumor suppressor gene and therefore serves as a novel therapeutic target for developing anti-cancer drugs. [BMB reports 2011; 44(4): 267-272]
INTRODUCTION
NFκB is a well known transcription factor that belongs to the Rel family of proteins. Originally, NFκB was identified as a protein that binds to specific sequences known as κB-motif, present in the enhancer elements of the immunoglobulin κ light chain gene (1, 2) . Subsequently, it was found to regulate the transcription of many genes involved in immunity, inflammation and disease (3) (4) (5) . NFκB, bound by inhibitor molecule IκB, is sequestered in the cytoplasm in unstimulated cells.
A wide range of extracellular stimuli, including inflammatory cytokine tumor necrosis factor (TNF) α and gram-negative bacteria endotoxin lipopolysaccharide (LPS), trigger signal transduction pathways to activate a downstream enzyme component, IκB kinase (IKK), which phosphorylates IκB to release NFκB. The released NFκB where nuclear localization signal is exposed, in turn, translocates into the nucleus and activates transcription of target genes.
Accumulating evidence suggests that aberrant activity of NFκB is critically involved in tumorigenesis. For example, mutations of the IκB gene have been identified in Hodgkin's lymphoma (6) , showing that the impaired function of IκBα contributes to the constitutive activation of NFκB. In addition, inhibition of NFκB by expression of a dominant-negative form of IκBα, called IκB Super Repressor, blocks focus formation induced by oncogenic H-Ras in NIH3T3 cells (7) . Consistent with this observation, Ras-induced transformation is highly suppressed by dominant-negative forms of IκB kinase (8) . Furthermore, it has been shown that the p65:p50 heterodimer of NFκB is constitutively translocated into nuclei of breast cancer cell lines and breast tumors (9) . Therefore, specific blockage of NFκB has emerged as an alternative and efficient way to suppress tumors having aberrant activation of NFκB.
TNFα is a pleiotropic pro-inflammatory cytokine that triggers diverse and important physiological events, including activation of NFκB and apoptosis (10, 11) . The binding of TNFα to its receptor, TNFR1, recruits TNFR1-associated death domain protein (TRADD) (12), TNF receptor-associated factor 2 (TRAF2) that triggers the activation of NFκB (11) , and FAS-associated death domain (FADD) protein that initiates apoptosis by activating caspase-8 (13) . As a result, TNFα simultaneously gives rise to signals that modulate cell survival and death through TRAF2 and FADD, respectively. NFκB plays a critical role in protecting cells from TNFα-driven apoptosis. The TNFα-activated NFκB translocates into the nucleus and activates four anti-apoptotic genes, TRAF1, TRAF2, c-inhibitor of apoptosis protein (IAP) 1 and c-IAP2, all of which are required to prevent cells from undergoing apoptosis by blocking caspase-8 activation (14) . Thus, if the balance between the signals of cell sur-http://bmbreports.org Thirty-six hours later, cells were treated with TNFα (20 ng/ml) for a further 12 hours. Normalized NFκB activity from κB-reporter is assigned to be 1. (B) ZAS3 increases TNFα-mediated apoptosis. HEK293 cells were co-transfected with pCH110 and indicated ZAS3 expression vectors (400 ng each). Duplicated transfectants were left untreated or treated with TNFα (20 ng/ml) for 12 hours. Cells were then fixed and stained with X-Gal overnight. The number of blue cells from four different fields was counted, and the averages of three experiments are presented. (C) ZAS3 increases TNFα-induced caspase-8 activity. Thirty-six hours after transfection with indicated plasmids, HEK293 cells were treated without or with TNFα (100 ng/ml) for 4 hours. Caspase-8 activities from cells transfected with empty vectors without TNFα treatment is assigned to be 1. Data shown represent the mean ± SEM from three independent experiments. vival and death is impaired, either signaling pathway is not properly regulated so that uncontrolled cell proliferation or death can occur.
ZAS3 is a large zinc finger protein containing two DNAbinding domains known as ZAS domains, which are separated widely apart. Each ZAS domain consists of two consecutive Cys2-His2 zinc fingers followed by a Glu/Asp-rich acidic region and Ser/Thr-stretch sequence. ZAS3 was originally cloned by its ability to bind V(D)J recombination signal sequence (Rss) flanking V, D and J exons of immunoglobulin genes (15) . Subsequent DNA-protein interaction studies showed that ZAS3 proteins have dual-DNA binding specificity for the Rss and κB-motif (16, 17) . In addition, it has been found that the deficiency of ZAS3 causes accelerated cell proliferation and tumor formation through aberrant activation of NFκB (18, 19) . NFκB constitutively translocated into the nuclei of ZAS3-deficient teratoma cell lines established from a ZAS3
RAG2
−/− chimeric mouse. Restoration of ZAS3 expression blocked the constitutive activation of NFκB in the nuclei (20) . Furthermore, a gain-of-function study has also demonstrated that ZAS3 strongly represses NFκB-activated transcription by competing with NFκB for the κB-motif in vitro (21) . Therefore, it has been proposed that there is a possible correlation between the tumor-inducing function and the transcription repression activity of ZAS3. However, the exact role of ZAS3 in the control of cell survival and death is still unclear.
Here, we show that ZAS3 increases TNFα-induced apoptosis by blocking NFκB-mediated cell survival. The overexpressed N-terminal region of ZAS3, where a transcription repression domain is included, increased TNFα-induced caspase-8 activity and apoptosis, the extent of which is at least equivalent to that of the dominant-negative form of IκB. Furthermore, transcription of TRAF1 and TRAF2, which are required to block NFκB-induced caspase cascade, is strongly repressed by the identical region of ZAS3. These results suggest that ZAS3 acts as a tumor suppressor gene by suppressing aberrant activation of anti-apoptotic genes.
RESULTS AND DISCUSSION

TNFα-induced apoptosis is sensitized by ZAS3
Our previous data showed that the lack of ZAS3 protein caused tumor formation through aberrant activation of NFκB (18, 20) . The possible involvement of ZAS3 in tumorigenesis prompted us to test if ZAS3 negatively modulates anti-apoptotic activity of NFκB. For this end, expression plasmids of ZAS3 (106-2013 amino acids) or IκB super-repressor (IκBSR) were first transfected into HEK293 cells with a luciferase reporter plasmid, followed by TNFα stimulation (Fig. 1A) . IκBSR is a dominant-negative form of IκB where IKK-phosphorylation sites (serines at positions 32 and 36) had been changed to alanines (22, 23) . TNFα increased the expression of the NFκB-reporter gene by 3-4 fold (Fig. 1A) . As expected, the overexpression of IκBSR strongly blocked TNFα-induced NFκB activation. Remarkably, ZAS3 abolished TNFα-induced NFκB activity as efficiently as IκBSR (Fig. 1A) . Consistent with the previous result that the transcriptional activity of ectopically expressed p65 and p50 is significantly inhibited by ZAS3 (21), http://bmbreports.org BMB reports this result indicates that ZAS3 almost completely represses NFκB-activated transcription upon TNFα stimulation. Next, we asked if the observed suppression of TNFα-induced NFκB activity correlates with cell survival and caspase-8 activity. Caspase-8 is the most upstream protease that receives the activation signal from TNFα to initiate the apoptotic protease cascade (24) . In general, TNFα-induced apoptosis is strongly attenuated by expression of anti-apoptotic genes activated by NFκB (14) . If the activity of NFκB in a cell is inhibited, the ultimate fate of the cell exposed to TNFα is determined by an apoptotic pathway triggered by a caspase cascade. In agreement with previous results, TNFα alone did not cause significant cell death in HEK293 cells (25) (Fig. 1B) . However, ectopic expression of ZAS3 (106-2013 and 106-750), IκBSR or a dominant-negative form of TRAF2 (TRAF2DN) (26) sensitized cells to TNFα-induced cell death (Fig. 1B) and the extent for the smallest ZAS3 protein (106-750) to promote TNFα-induced cell death was similar to or even stronger than that of TRAF2DN. TRAF2DN is a mutant of human TRAF2, where the RING domain was deleted, functioning to lock signals to activate NFκB and c-Jun N-terminal kinase (JNK). Consistently, the C-terminal half of ZAS3 (1186-2153) showed the weakest repression activity (21) and had little effect on TNFα-induced cell death. TRAF2DN and IκBSR blocked translocation of NFκB into the nucleus, whereas ZAS3 seemed to inhibit NFκB through DNA competition for the κB-motif. In keeping with their efficiency of sensitizing cells to TNFα-induced cell death, caspase-8 activity was higher in cells overexpressing ZAS3 or IκBSR than those transfected with the empty vector upon TNFα treatment (Fig. 1C) . Together, these findings indicate that the activity of ZAS3 to sensitize cells to TNFα-induced cell death is largely dependent on the repression activity of ZAS3 and suggest that the increased TNFα-induced cell death is derived from the elevated activity of caspase-8 through activation of FADD.
ZAS3 neither directly associates with NFκB nor affects nuclear localization of NFκB in TNF-α stimulated cells
We investigated the mechanism by which ZAS3 regulates NFκB activity in TNF-α stimulated cells. Since it was found that ZAS3 represses NFκB-activated transcription by direct competition with NFκB for κB-motif (21), there was a possibility that the repression effect of ZAS3 on NFκB is at least partly due to direct interaction between ZAS3 and NFκB. To determine if ZAS3 directly associates with NFκB, bacterially expressed glutathione-S-transferase (GST) fusion proteins of p65, p50 and ZAS3 were used in co-immunoprecipitation studies. ZAS3 is a large zinc finger transcription repressor that contains two widely separated DNA binding and protein-interacting domains, designated ZASN and ZASC, which bind to DNA independently (27) (Fig. 2A) . Two ZAS3 fusion proteins, GST-106-750 and GST-1497-2153, were prepared (Fig. 2B) , since 645 amino acids of GST-106-750 containing the ZASN domain showed the strongest repression activity and in contrast GST-1497-2153 showed the weakest on NFκB-activated transcription (21) . None of the ZAS3 fusion proteins directly http://bmbreports.org Forty-eight hours after transfection, cytoplasmic mRNA was isolated and semi-quantitative RT-PCR was performed with specific primer sets. GAPDH was used as a loading control. (B) Forty-eight hours after transfection, cytoplasmic (CE) and nuclear (NE) fractions of transfected cells were separated and Western blot analyses were performed with specific antibodies. Cross-contamination between cytoplasmic and nuclear fractionations during the preparation was confirmed by the expression of hsp90 and histone H1 in cytoplasmic and nuclear fraction, respectively. interacted with p65, p50 or the heterodimer of p65 and p50 (Fig. 3) , which is consistent with the previous result that DNA-protein complexes with intermediate gel mobility between fusion proteins of ZAS3 and NFκB do not form in electrophoretic mobility shift assay (21) .
The fact that NFκB is constitutively translocated into the nuclei of ZAS3 knock-out cells (20) raised a possibility that ZAS3 affects nuclear localization of NFκB in TNF-α stimulated cells. To test the possibility, p65, p50 and ZAS3 were ectopically expressed in HEK293 cells and then their localization was examined in nuclear and cytoplasmic fractions separately (Fig. 4B,  bottom panel) . Interestingly, expression of p65 and p50 proteins was observed not only in the cytoplasmic fraction (data not shown) but also in the nuclear fraction, most likely due to saturation of IκB when p65 and p50 were overexpressed. In addition, their nuclear localization was not affected by any ZAS3 protein. Taken together, these data indicate that ZAS3 neither affects the localization of NFκB nor directly associates with NFκB.
ZAS3 represses expression of TRAF1 and TRAF2 to promote TNFα-driven apoptosis
To further investigate the mechanisms underlying the regulatory effect of ZAS3 on NFκB, we measured the expression of NFκB target genes in the presence of ZAS3 proteins. Since the anti-apoptotic activity of NFκB originates from the increased expression of four anti-apoptotic genes, TRAF1, TRAF2, c-IAP1 and c-IAP2 (14), we tested whether ZAS3 represses expression of the anti-apoptotic genes to negatively modulate NFκB-dependent anti-apoptosis. To measure expression of the four genes in the presence or absence of ZAS3 proteins, ZAS3 expression plasmids (106-750 and 1186-2153) were transfected into HEK293 cells with or without expression plasmids for p65 and p50, and then the expression of the four genes was monitored for the level of RNA and protein (Fig. 4) . The increasing amount of p65 and p50 activated expression of TRAF1 and TRAF2 in a dose-dependent manner, which was diminished by ZAS3106-750 containing the ZASN domain, but not by ZAS31185-2153 containing the C-terminal half (Fig. 4A and  4B ). Despite the initial reports that c-IAP1 and c-IAP2 were under the control of NFκB (14), neither NFκB (p65 and P50) nor ZAS3 had any significant effect on the expression of these anti-apoptotic genes. The repressed expression of TRAF1 and TRAF2 by ZAS3 seemed to be sufficient to increase TNFα-induced apoptosis since NFκB-dependent anti-apoptosis required expression of all of the four anti-apoptotic genes (14) . These results suggest that ZAS3 enhances TNFα-induced apoptosis through repressing the transcription of TRAF1 and TRAF2 activated by NFκB. In line with this, our previous data showed that ZAS3 can compete for the κB DNA binding motif with NFκB (21) . Taken together, our results strengthen the notion that ZAS3 inhibits NFκB-dependent expression of anti-apoptotic genes by directly competing for the κB-motif.
In this study, we show for the first time that ZAS3 promotes TNFα-induced apoptosis by repressing NFκB-activated expression of anti-apoptotic genes. It is possible that the downregulation of ZAS3 may relieve DNA competition with NFκB for the κB-motif, consequently inducing the uncontrolled expression of NFκB-dependent anti-apoptotic genes. This speculation is also likely to explain the previous observation that a tumor occurred in a ZAS3-knock-out mouse (18) and suggests that ZAS3 plays a critical role as a tumor suppressor gene to repress deviated expression of NFκB-target genes.
Expression plasmids for p65 and p50 were also exploited to activate expression of NFκB-target genes instead of TNFα since we wanted to exclude the possible interference of other transcription factors also activated by TNFα. The TNFα signaling pathway through TNFR1 diverges to activate at least two different downstream kinases, IKK and JNK, so that each kinase relays the signal to its terminal targets of transcription factors such as NFκB, AP-1 and ATF-2 (11, 28, 29) . Thus, the finding that ZAS3 repressed transcription of TRAF1 and TRAF2 activated by p65 and p50 proves again that ZAS3 functions as a transcriptional repressor to inhibit transcription from promoters of genuine NFκB-target genes in cultured cells. Intriguingly, ZAS3 failed to repress expression of all of the four NFκB-dependent anti-apoptotic genes activated by overexpression of p65 and p50. The two genes, c-IAP1 and c-IAP2, whose expression was not influenced by ZAS3, did not even respond to the overexpression of p65 and p50 in the absence of ZAS3. This finding is not consistent with the previous result that IκBSR-mediated blockage of NFκB simultaneously repressed transcription of the four anti-apoptotic genes induced by TNFα (14) . The simplest explanation for this inconsistency would be the lack of one or more transcription factors also activated by TNFα, i.e., the expression of p65 and p50 is necessary but not sufficient to activate c-IAP1 and c-IAP2. Since the TNFα signaling pathway diverges at TRAF2 to produce two different transcriptional outcomes, it is conceivable that the JNK-activated transcription factors including AP-1 and ATF-2 are involved in activation of both genes. Another possibility might be cell-type specific differentiation of anti-apoptotic gene expression. In the resting state, the expression of c-IAP1 and c-IAP2 seems to be relatively high compared to that of TRAF1 and TRAF2 in HEK293 cells (Fig. 4A and 4B ), whereas the differentiation between the uninduced and the induced expression of c-IAP1 and c-IAP2 genes is hardly distinguishable in the HT1080I human cell line (14) . It is possible that HEK293 cells already express enough c-IAP1 and c-IAP2.
In addition to the IκB family proteins (30, 31) , the ZAS3 protein has emerged as a novel, potent, endogenous inhibitor of NFκB. Because NFκB and ZAS3 proteins share similar DNA target sites, the forced expression of the endogenous ZAS3 gene could inevitably and specifically inhibit the transcriptional activity of NFκB, thereby providing opportunities to develop novel strategies for the intervention of malignant transformation.
MATERIALS AND METHODS
Detailed information is described in Supplementary Material.
